CRISIL is not a stock broker which is not serious about its buy calls and target prices. Indeed, CRISIL’s ‘analysts’ are supposed to be more hardnosed than equity analysts, given that CRISIL is an ‘expert’ in rating debt. If so, what can explain this kind of analysis and recommendation? Vested interest?
One of the biggest names in the business of analysis, Credit Rating and Information Services India (CRISIL), seems to be habitually making blunders in its equity analysis. This time we bring you the story of Spanco. Ever since CRISIL started covering Spanco, back in 2011, the stock has only nosedived from Rs133 to less Rs16 (at the time of writing this piece)! What is interesting (or should we say shocking?) is that CRISIL had stubbornly stuck to the target price of Rs289, according to an interesting blog alphaideas.in, which keeps track of forecasting errors.
In CRISIL’s initial coverage report which was published on 28 July 2011, the ratings agency said: “We maintain our fair value of Rs289 per share and valuation grade of 5/5.” Furthermore, it stated, “We maintain the fundamental grade of 3/5, indicating that Spanco’s fundamentals are good relative to other listed securities in India.” The prevailing price was Rs133 then.
Fast forward little over a year, Spanco tanked to Rs69. In the face of this share price decline, CRISIL’s analysts stood firm. They came up with yet another report on Spanco, on 11 May 2012. In this report, they restated almost the exact same thing: “Post further interaction with the management, we will introduce FY13 forecast and revisit our estimates and fair value. At the current market price of Rs 69, our valuation grade is 5/5.” It even said, “We maintain our fundamental grade of 3/5.”
Today, the share price is below Rs16, or 94.46% down from CRISIL’s original target price of Rs289. This is not a big error—it is a massive dislocation from the forecast. This isn’t the first time that CRISIL has made this sort of error. It has done a similar sort of thing for Everest Kanto Cylinders (EKC). Sometime in October 2010, it had given EKC a rating of 4/5 and a target price of Rs146 (the prevailing price was Rs124). Two years later, on 29 November 2012, the price tanked nearly 78% to Rs28 while the company gave it a target price of Rs33!
However, we noticed something very odd in CRISIL’s second report. Somehow, the Spanco which was then experiencing difficulties in servicing debt obligations suddenly improved its collection period almost overnight. CRISIL’s report stated, “Spanco’s credit rating was downgraded from CARE B to CARE D on 6 April 2012 due to delays in servicing of debt obligations. The grade was then revised on 30 April 2012 to CARE C. According to the ratings agency, this was due to an improvement in the collection period and consequent improvement in the debt servicing by the company.” When the rating is revised from CARE B grading to CARE C grading that should set off alarm bells for a “fundamental analyst”. Just because it went up from CARE D to CARE C grading doesn’t mean the target price of Rs289 should be maintained. We see the anchoring bias at play here, when the reference level is CARE D and not CARE B grading. This bias is quite common.
This isn’t the first time that we have written about CRISIL’s fishy reports with a special penchant for giving 5/5 to junk or near-junk stocks.
Earlier we wrote how it rated 5/5 for Helios & Matheson a small-time software company based in Chennai despite a pending criminal case against its chairman and MD. The Enforcement Directorate (ED) is currently pursuing investigations against Mr Ramachandran and Mr Muralikrishna, the chairman and director of Helios & Matheson respectively. When this sort of thing is going on, it is an obvious red flag. Unfortunately, this was ignored or overlooked by CRISIL’s analysts.
Click here to read the Helios & Matheson story.
It is common to find stockbrokers coming out with buy recommendations on stocks that lose 80%-90% of their value. They usually have some vested interest. Earlier this year, we had written about Opto Circuits, when broker ICICIdirect kept a BUY on the company even as the share price of Opto Circuits was careening downwards.
Click here to check the ICICIdirect and Opto Circuit story.
Then there’s the case of Arshiya International when Kotak Securities had predicted that it would be the best performer of this year. Instead, the share price has tanked 75% since their call.
Click here for the Arshiya International and Kotak story.
But it is quite remarkable for an ‘independent’ research agency, that has a through grounding in dealing with more conservative world of debt securities to come out with 5/5 recommendations not on blue chips, not on solid mid-caps, but on stocks turn out to be hollow.
One of the crucial components of making a good forecast is not so much to be just close to the mark, though it is important to be as accurate as possible, but revaluating forecasts based on new information. This is what sets apart great forecasters from ordinary hacks. Even great forecasters and analysts make mistakes but they do re-evaluate based on fresh information and give their logical reasons why. When new material information is revealed, it is imperative that it will have a huge bearing on the forecast and target price. What is shocking about CRISIL’s forecast of Spanco is that its share price kept going down while it stubbornly stuck to its original forecast. The analysts in CRISIL should have at least investigated the decline in its share price and the reason behind it.
Rating agencies like Standard & Poor (S&P) which the parent company of CRISIL and Moody’s came under heavy fire in the United States for their flawed forecast of high risk mortgage securities which they stamped as high-grade. The United States government recently filed a class-action lawsuit against S&P for its role in the sub-prime crisis. CRISIL’s rating quality in equity stocks indicates that no lesson has been learnt. Analysts remain as unaccountable as before.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam

Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.

Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.

Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )

What is really more surprising for me is the way you write and get ready for a mud-slinging game on other firms and analysts! You have written about ICICI, HDFC, Kotak, CRISIL etc etc but you for got your own article "Sweet Pill" on Surya Pharmacy which investors might have bit the dust and as a matter of fact that your call is even worse than any of the above miss calls. You cleverly or ignorantly not mentioned that example. WHY? Becuase it is from your own house yet got ready to sling on others!
1. Moneylife article dated Mar 24, 2011 about Surya Pharmacy titled "Sweet Pill".
2. MoneyLife article dated June 18, 2010 about Surya Pharmacy titled "Perfect prescription".
Now as a reader, I give you two choices:
1. You never written any follow up article on your worst call Surya Pharmacy. Yet mud-sling others. Why?
2. Delete my comment before your readers realize your double standards :)
The choice is yours, answer or delete?
1. All Moneylife readers know (casual mudslingers like you need to be educated) that we recommended a precise stop-loss and stop-profit till 2011. On this basis, anybody buying Surya Pharma would have been out of the stock at a substantial profit. What a surprise for you, right? Snotty analysts of Crisil and other places do not even know that is a stop profit and a stop loss.
2. Since 2012, we have offered a review of our recommendations in every issue, on an ongoing basis. No other publication does this. I guess you have either not noticed, or prefer to ignore it because how would it fit into your vile mind.
3. Since there are careless readers who read selectively and act selectively, from 2012, we have dispensed with the automatic stop-loss and stop-profit formula, which used to be there at the bottom of Street Beat in each issue. We have replaced this with ongoing review and recommendations so that nobody is every in doubt about our current call on a stock we have recommended in the past.
4. Those who read Moneylife you will know that we are the only publication, which has been doing a yearly review of our stock recommendation with all the hits and misses. Our performance has been excellent year after year, even in a declining market.
You are free to comment here but if you learn to be factual. Otherwise we will surely delete your comment and block you. I simply do not have the time to read your trash and compose a reply for loathsome creatures like you.
And while we are at it, here is a reader response to the quality of our stock analysis. Read and burn inside, given how full of bile you are.
http://www.moneylife.in/article/frank-an...
1. Debt
2. Pledging of shares
3. Low promoter holding
4. Margin trigger
5. Poor performance
All the above five are coupled with each other.
SEBI must wake up and prove it is doing it's job.
check out and you may find many more worms in the can. apparently reports are influenced only to fulfil certain nefarious designs of promoters and/or some other vested interests.small time investors or should i say traders are being parted from their money by these tools used by such respected and highly regarded names of the financial world.vry vry sad.....!